A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

Full Title

A Pilot Study of Neoadjuvant mFOLFIRINOX and ELI002-7P treatment with or without Tislelizumab in Borderline and Resectable Pancreatic Ductal Adenocarcinoma

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Kevin Soares’ office at 212-639-3195.

Protocol
25-386
Phase
Phase I (phase 1)
Investigator